Home Biogen

Biogen

Looking to expand your partner network with leading companies like Biogen? Consider joining Inpart's global network for free.

Stay informed about the latest news about Biogen by subscribing to our newsletter.

What is Biogen best known for?

Biogen is renowned for its neuroscience advancements and innovative therapies for neurological diseases. Notably, it has made significant contributions to multiple sclerosis treatment with Tysabri and gained global attention for its breakthrough Alzheimer’s drug, Aduhelm.

Where is Biogen located?

Biogen is headquartered in Cambridge, Massachusetts, United States. Biogen also has a global presence with offices and operations in various countries worldwide, including Canada, Europe, Japan, and other regions.

Got a news story for us related to Biogen? Send it to us here.

Latest Posts

Best in Biotech 15 Aug 2024

10 neuroscience biotech companies you should know about

Learn more about nine of the top neuroscience biotech companies looking to develop treatments for difficult-to-treat neurological conditions.

August 15, 2024 - 12 minutesmins - By Willow Shah-Neville

Biogen's transition from Aduhelm to Leqembi: a new chapter in Alzheimer's drug development

In Depth 15 Feb 2024

Biogen: how is the biotech giant pivoting from a failed Alzheimer’s drug?

Learn more about Biogen’s strategic realignment from Aduhelm’s controversy to Leqembi’s promise in Alzheimer’s treatment.

February 15, 2024 - 11 minutesmins - By Jules Adam

In Depth 26 Oct 2023

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

Alzheimer’s disease is the most common form of dementia – which currently affects more than 55 million people globally – making up 60% to 70% of cases. It is a complex disease, encompassing multiple interrelated and progressive destructive processes in the brain, resulting in neuron damage that extends to parts of the brain that enable […]

October 26, 2023 - 11 minutesmins - By Willow Shah-Neville

News and Trends 31 Jul 2023

Biogen acquiring Reata Pharmaceuticals for $7.3B

Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is […]

July 31, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

FDA approves Alzheimer’s treatment

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use. The decision makes LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression […]

July 7, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Biogen ALS drug gets FDA ok

The U.S. Food and Drug Administration (FDA) has approved Biogen’s QALSODY (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients […]

April 27, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline

Sometimes, there’s an interview that we do that’s just a bit long for the regular podcast. So we’re going to start an occasional series of podcasts where we look a bit more in depth at a condition, and what’s the current state of affairs in treatment. In this podcast, the first, we take a closer […]

February 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease

BioArctic AB’s partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab. Lecanemab, known as LEQEMBI in the U.S., is an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed […]

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward

A huge step forward in dementia research has been hailed a truly historic moment by researchers working to find a cure for people with Alzheimer’s Disease. This is the first time a drug being trialed, lecanemab, has shown a reduction in the disease in the brain while slowing memory decline. Dr Susan Kohlhaas, director of […]

November 30, 2022 - 6 minutesmins - By Liza Laws

More News! 29 Sep 2022

Positive results from Eisai and Biogen Alzheimer’s trial

Eisai Co., Ltd. and Biogen Inc. have announced positive topline results from Eisai’s large global phase 3 confirmatory Clarity AD clinical trial of lecanemab to treat mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. Lecanemab is an […]

September 29, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 17 Jun 2021

FDA Approval of Biogen’s Drug Boosts European Alzheimer’s Space

The FDA shocked many life sciences observers by greenlighting Biogen’s treatment candidate for Alzheimer’s last week. Yet, for much of the Alzheimer’s disease community on both sides of the Atlantic, the decision also brings cautious hope. Controversy recently erupted when the FDA conditionally granted accelerated approval to Biogen’s aducanumab, making it the first approved treatment […]

June 17, 2021 - 6 minutesmins - By Victor Kotsev

multiple sclerosis novartis roche ema approval

News and Trends 27 Apr 2021

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […]

April 27, 2021 - 6 minutesmins - By Jonathan Smith

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Biogen

What is Biogen best known for?

Where is Biogen located?

10 neuroscience biotech companies you should know about

Biogen: how is the biotech giant pivoting from a failed Alzheimer’s drug?

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

Biogen acquiring Reata Pharmaceuticals for $7.3B

FDA approves Alzheimer’s treatment

Biogen ALS drug gets FDA ok

Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline

EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease

‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward

Positive results from Eisai and Biogen Alzheimer’s trial

FDA Approval of Biogen’s Drug Boosts European Alzheimer’s Space

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!